ADC In Vivo Analysis

Antibody-drug conjugates (ADCs) are innovative next-generation immune therapy agents that combine the specific targeting capacity of a monoclonal antibody with cytotoxic drugs. They are designed for accurate drug delivery to minimize collateral damages to healthy tissues. With the antibody Fc region that triggers antibody dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) and the cytotoxicity of the payload drug, some ADCs exert a “two-fold” killing efficacy towards targeted cancer cells.
https://www.creative-biolabs.com/adc/adc-in-vivo-analysis.htm